Evidence map›Paper›PMID 41824221›Full record

ArticleEJNMMI research2026

Comparison between [

Alina Toni Küper, Sofia Carrilho Vaz, Kim Magaly Pabst, Ieva Ciuciulkaite, Ilektra Antonia Mavroeidi, Rainer Hamacher, Anja Welt, Noah Hammersen, Pedro Fragoso Costa, Loic Djaileb and 7 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04571086 (68-Ga-FAPI-PET for Tumor Detection), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04571086 recruitingnot on this map

68-Ga-FAPI-PET for Tumor Detection: A Prospective Observational Trial

Typeobservational_patient_registrySponsorUniversity Hospital, EssenRan2020 to 2027Enrolled500ConditionsMalignant Neoplasm
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alina Toni Küper *Department of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Alina.Kueper@uk-essen.de.ORCID http://orcid.org/0009-0009-4380-1629
Sofia Carrilho Vaz *Department of Nuclear Medicine and Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
Kim Magaly PabstDepartment of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Ieva CiuciulkaiteDepartment of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Ilektra Antonia MavroeidiDepartment of Medical Oncology, NCT site, University Hospital Essen, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
Rainer HamacherDepartment of Nuclear Medicine and Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
Anja WeltDepartment of Medical Oncology, NCT site, University Hospital Essen, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
Noah HammersenDepartment of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Pedro Fragoso CostaDepartment of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Loic DjailebNuclear Medicine Department, LRB, CHU Grenoble Alpes, INSERM, Université Grenoble Alpes, Grenoble, France.
Robert SeifertDepartment of Nuclear Medicine, University Hospital Bern, University of Bern, Bern, Switzerland.
Lale UmutluInstitute of Interventional and Diagnostic Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Martin SchulerDepartment of Medical Oncology, NCT site, University Hospital Essen, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
Ken HerrmannDepartment of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Wolfgang Peter FendlerDepartment of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Sherko KümmelBreast Unit Essen, Kliniken Essen-Mitte, Essen, Germany.
David KerstingDepartment of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFibroblast activation protein (FAP)-targeted tracers have emerged as promising agents for breast cancer imaging, with recent studies demonstrating PET performance comparable to or surpassing, that of [

resultsThirteen patients were included. Overall, the detection performance was comparable between [

conclusionIn this small exploratory cohort, comparable uptake patterns in [

trial registration68-Ga-FAPI-PET for Tumor Detection: A Prospective Observational Trial, NCT04571086, 09-15-2020, https://clinicaltrials.gov/study/NCT04571086 .

Indexed as

Breast cancerFAPIFDGHER2Hormone receptorsLuminal-likePan-tumour imagingPETTheranostics

Identifiers

PMID41824221
PMCPMC13066216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.